Research Papers:

The long non-coding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large B-cell lymphoma

Shuangtao Zhao, Shuangsang Fang, Yanhua Liu, Xixi Li, Shengyou Liao, Jinwen Chen, Jingjia Liu, Lianhe Zhao, Hui Li, Wei Zhou, Wenzhi Shen, Xiaoli Dong, Rong Xiang, Luhua Wang and Yi Zhao _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:34374-34386. https://doi.org/10.18632/oncotarget.16163

Metrics: PDF 1145 views  |   HTML 1891 views  |   ?  


Shuangtao Zhao1,*, Shuangsang Fang2,*, Yanhua Liu3,4,5,*, Xixi Li3,6, Shengyou Liao2, Jinwen Chen2, Jingjia Liu2, Lianhe Zhao2, Hui Li2, Wei Zhou3,4,5, Wenzhi Shen3,4,5, Xiaoli Dong3,4,5, Rong Xiang3,4,5, Luhua Wang1, Yi Zhao2

1Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

2The Key Laboratory of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China

3The School of Medicine, Nankai University, Tianjin, China

4The Collaborative Innovation Center for Biotherapy, Nankai University, Tianjin, China

5The Tianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Tianjin, China

6Department of Pathology, Nankai University, Tianjin, China

*Co-first author

Correspondence to:

Rong Xiang, email: rxiang@nankai.edu.cn

Luhua Wang, email: wlhwq@yahoo.com

Yi Zhao, email: biozy@ict.ac.cn

Keywords: diffuse large B-cell lymphoma, long non-coding RNA, NONHSAG026900, prognosis, biomarker

Received: January 17, 2017     Accepted: February 24, 2017     Published: March 13, 2017


Long non-coding RNAs are known to be involved in cancer progression, but their biological functions and prognostic values are still largely unexplored in diffuse large B-cell lymphoma. In this study, long non-coding RNAs expression was characterized in 1,403 samples including normal and diffuse large B-cell lymphoma by repurposing 7 microarray datasets. Compared with any stage of normal B cells, NONHSAG026900 expression was significantly decreased in tumor samples. And in germinal center B-cell subtype, the significantly higher expression of NONHSAG026900 indicated it was a favorable prognosis biomarker. Then the prognostic power of NONHSAG026900 was validated with another independent dataset and NONHSAG026900 improved the predictive power of International Prognostic Index as an independent factor. Moreover, functional prediction and validation demonstrated that NONHSAG026900 could inhibit cell cycle activity to restrain tumor proliferation. These findings identified NONHSAG026900 as a novel prognostic biomarker and offered a new therapeutic target for diffuse large B-cell lymphoma patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16163